Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis

Detalhes bibliográficos
Autor(a) principal: Castro, Nathalie de
Data de Publicação: 2022
Outros Autores: Chazallon, Corine, N'takpe, Jean-Baptiste, Timana, Isabel, Escada, Rodrigo, Wagner, Sandra, Messou, Eugène, Eholie, Serge, Bhatt, Nilesh, Khosa, Celso, Laureillard, Didier, Chau, Giang do, Veloso, Valdiléa G., Delaugerre, Constance, Anglaret, Xavier, Molina, Jean-Michel, Grinsztejn, Beatriz, Marcy, Olivier
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/60235
Resumo: The ANRS 12300 Reflate TB2 trial was funded by the National French Research Agency on HIV/AIDS and emerging infectious diseases (ANRS|MIE), the Brazilian Ministry of Health in Brazil, and Merck and Co.
id CRUZ_db06bedc6e78a4b62c09a1dd866dc07c
oai_identifier_str oai:www.arca.fiocruz.br:icict/60235
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Castro, Nathalie deChazallon, CorineN'takpe, Jean-BaptisteTimana, IsabelEscada, RodrigoWagner, SandraMessou, EugèneEholie, SergeBhatt, NileshKhosa, CelsoLaureillard, DidierChau, Giang doVeloso, Valdiléa G.Delaugerre, ConstanceAnglaret, XavierMolina, Jean-MichelGrinsztejn, BeatrizMarcy, Olivier2023-08-25T23:48:14Z2023-08-25T23:48:14Z2022CASTRO, Nathalie de et al. Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis. Open Forum Infectious Diseases, v. 9, n. 12, p. 1-9, Nov. 2022.2328-8957https://www.arca.fiocruz.br/handle/icict/6023510.1093/ofid/ofac6282328-8957The ANRS 12300 Reflate TB2 trial was funded by the National French Research Agency on HIV/AIDS and emerging infectious diseases (ANRS|MIE), the Brazilian Ministry of Health in Brazil, and Merck and Co.Bordeaux Population Health Centre. Research Institute for Sustainable Development (IRD) EMR 271. National Institute for Health and Medical Research (INSERM) UMR 1219. University of Bordeaux. Bordeaux, France / Infectious Diseases Department. AP-HP-Hôpital Saint-Louis Lariboisière. Paris, France.Bordeaux Population Health Centre. Research Institute for Sustainable Development (IRD) EMR 271. National Institute for Health and Medical Research (INSERM) UMR 1219. University of Bordeaux. Bordeaux, France.Bordeaux Population Health Centre. Research Institute for Sustainable Development (IRD) EMR 271. National Institute for Health and Medical Research (INSERM) UMR 1219. University of Bordeaux. Bordeaux, France / Programme PACCI/ANRS Research Center. Abidjan, Côte-d'Ivoire.Instituto Nacional de Saúde. Marracuene, Mozambique.Oswaldo Cruz Foundation. National Institute of Infectious Diseases Evandro Chagas. Rio de Janeiro, RJ, Brazil.Oswaldo Cruz Foundation. National Institute of Infectious Diseases Evandro Chagas. Rio de Janeiro, RJ, Brazil.Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire / Centre de Prise en Charge de Recherche et de Formation, CePReF-Aconda-VS. Abidjan, Côte-d'Ivoire.Programme PACCI/ANRS Research Center, Abidjan, Côte-d'Ivoire / Département de Dermatologie et d'Infectiologie, UFR des Sciences Médicales, Université Félix Houphouët Boigny. Abidjan, Cote d'Ivoire.Instituto Nacional de Saúde. Marracuene, Mozambique.Instituto Nacional de Saúde. Marracuene, Mozambique.Department of Infectious and Tropical Diseases. Nimes University Hospital. Nimes, France / Pathogenesis and Control of Chronic and Emerging Infections. University of Montpellier. Montpellier, France.Pham Ngoc Thach Hospital. Ho Chi Minh City, Vietnam.Oswaldo Cruz Foundation. National Institute of Infectious Diseases Evandro Chagas. Rio de Janeiro, RJ, Brazil.Virology Department. APHP-Hôpital Saint-Louis. Paris, France / INSERM U944. Paris, France / Université de Paris. Paris, France.Bordeaux Population Health Centre. Research Institute for Sustainable Development (IRD) EMR 271. National Institute for Health and Medical Research (INSERM) UMR 1219. University of Bordeaux. Bordeaux, France.Infectious Diseases Department. AP-HP-Hôpital Saint-Louis Lariboisière. Paris, France / INSERM U944. Paris, France / Université de Paris. Paris, France.Oswaldo Cruz Foundation. National Institute of Infectious Diseases Evandro Chagas. Rio de Janeiro, RJ, Brazil.Bordeaux Population Health Centre. Research Institute for Sustainable Development (IRD) EMR 271. National Institute for Health and Medical Research (INSERM) UMR 1219. University of Bordeaux. Bordeaux, France.Background: In people with human immunodeficiency virus [HIV] presenting with advanced disease, rates of virologic success may be lower than expected. The Reflate TB2 trial did not show non-inferiority of raltegravir versus efavirenz in people with HIV (PWH) treated for tuberculosis. We aimed to identify factors associated with virologic success and higher adherence in the trial. Methods: In this analysis, we included participants enrolled in the Reflate TB2 trial with adherence data available. The primary outcome was virologic success (HIV-1 ribonucleic acid [RNA] <50 copies/mL) at week 48, and the secondary outcome was adherence as assessed by the pill count adherence ratio. We used logistic regression to study determinants of virologic success and optimal adherence in 2 separate analyses. Results: Four hundred forty-four participants were included in the present analysis. Over the 48-week follow-up period, 290 of 444 (65%) participants had a pill count adherence ratio ≥95%. At week 48, 288 of 444 (65%) participants were in virologic success. In the multivariate analysis, female sex (adjusted odds ratio [aOR], 1.77; 95% confidence interval [CI], 1.16-2.72; P = .0084), lower baseline HIV-1 RNA levels (<100 000; aOR, 2.29; 95% CI, 1.33-3.96; P = .0087), and pill count adherence ratio ≥95% (aOR, 2.38; 95% CI, 1.56-3.62; P < .0001) were independently associated with virologic success. Antiretroviral pill burden was the only factor associated with pill count adherence ratio ≥95% (OR, 0.81; 95% CI, .71-.92; P = .0018). Conclusions: In PWH with tuberculosis receiving raltegravir or efavirenz-based regimens, female sex, optimal adherence, and baseline HIV-1 RNA <100 000 copies/mL were associated with virologic success, and the number of antiretroviral tablets taken daily was a strong predictor of adherence.engOxford University PressDeterminants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosisinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleHIV viral loadAdherenceRaltegravirTuberculosisinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/60235/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALve_Nathalie_Castro_etal_INI_2022.pdfve_Nathalie_Castro_etal_INI_2022.pdfapplication/pdf401332https://www.arca.fiocruz.br/bitstream/icict/60235/2/ve_Nathalie_Castro_etal_INI_2022.pdf1f74b06c2800958c8dc6415c0002d93bMD52icict/602352023-08-25 20:48:15.741oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-08-25T23:48:15Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.en_US.fl_str_mv Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
title Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
spellingShingle Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
Castro, Nathalie de
HIV viral load
Adherence
Raltegravir
Tuberculosis
title_short Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
title_full Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
title_fullStr Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
title_full_unstemmed Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
title_sort Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis
author Castro, Nathalie de
author_facet Castro, Nathalie de
Chazallon, Corine
N'takpe, Jean-Baptiste
Timana, Isabel
Escada, Rodrigo
Wagner, Sandra
Messou, Eugène
Eholie, Serge
Bhatt, Nilesh
Khosa, Celso
Laureillard, Didier
Chau, Giang do
Veloso, Valdiléa G.
Delaugerre, Constance
Anglaret, Xavier
Molina, Jean-Michel
Grinsztejn, Beatriz
Marcy, Olivier
author_role author
author2 Chazallon, Corine
N'takpe, Jean-Baptiste
Timana, Isabel
Escada, Rodrigo
Wagner, Sandra
Messou, Eugène
Eholie, Serge
Bhatt, Nilesh
Khosa, Celso
Laureillard, Didier
Chau, Giang do
Veloso, Valdiléa G.
Delaugerre, Constance
Anglaret, Xavier
Molina, Jean-Michel
Grinsztejn, Beatriz
Marcy, Olivier
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Castro, Nathalie de
Chazallon, Corine
N'takpe, Jean-Baptiste
Timana, Isabel
Escada, Rodrigo
Wagner, Sandra
Messou, Eugène
Eholie, Serge
Bhatt, Nilesh
Khosa, Celso
Laureillard, Didier
Chau, Giang do
Veloso, Valdiléa G.
Delaugerre, Constance
Anglaret, Xavier
Molina, Jean-Michel
Grinsztejn, Beatriz
Marcy, Olivier
dc.subject.en.en_US.fl_str_mv HIV viral load
Adherence
Raltegravir
Tuberculosis
topic HIV viral load
Adherence
Raltegravir
Tuberculosis
description The ANRS 12300 Reflate TB2 trial was funded by the National French Research Agency on HIV/AIDS and emerging infectious diseases (ANRS|MIE), the Brazilian Ministry of Health in Brazil, and Merck and Co.
publishDate 2022
dc.date.issued.fl_str_mv 2022
dc.date.accessioned.fl_str_mv 2023-08-25T23:48:14Z
dc.date.available.fl_str_mv 2023-08-25T23:48:14Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv CASTRO, Nathalie de et al. Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis. Open Forum Infectious Diseases, v. 9, n. 12, p. 1-9, Nov. 2022.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/60235
dc.identifier.issn.en_US.fl_str_mv 2328-8957
dc.identifier.doi.none.fl_str_mv 10.1093/ofid/ofac628
dc.identifier.eissn.none.fl_str_mv 2328-8957
identifier_str_mv CASTRO, Nathalie de et al. Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis. Open Forum Infectious Diseases, v. 9, n. 12, p. 1-9, Nov. 2022.
2328-8957
10.1093/ofid/ofac628
url https://www.arca.fiocruz.br/handle/icict/60235
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Oxford University Press
publisher.none.fl_str_mv Oxford University Press
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/60235/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/60235/2/ve_Nathalie_Castro_etal_INI_2022.pdf
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
1f74b06c2800958c8dc6415c0002d93b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324793185927168

Registros relacionados